Clinical Trial Update: Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway [Phase 1]

View source ↗

Summary

Phase 1 study evaluating DVS SR for inhibiting the CYP2D6 pathway has completed, sponsored by Wyeth (Pfizer).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy
• Fibromyalgia
• Major Depressive Disorder
• Menopausal Vasomotor Symptoms

Drugs mentioned

• DVS SR

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Depressive Disorder, Major, Diabetic Neuropathies | Phase 1 | Status: COMPLETED